Navigation Links
CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis
Date:10/15/2009

y.

Upon analysis of the primary efficacy results, the mean CFA was greater during treatment with CREON® (82.8%) compared to treatment with placebo (47.4%), which resulted in a significant difference of 35.4% (p < 0.001). Thus, the study met its primary objective and showed a superior efficacy of CREON® over placebo based on the CFA. Treatment-emergent adverse events, which were predominantly gastrointestinal events, were reported in five patients during treatment with CREON® and nine patients during treatment with placebo.

About Exocrine Pancreatic Insufficiency and Pancreatic Enzyme Replacement Therapies

Exocrine pancreatic insufficiency (EPI) is a condition resulting from a deficiency in the production and/or secretion of pancreatic enzymes that are necessary to digest nutrients in food. The safety and efficacy of prior formulations of pancrelipase in pediatric patients with EPI due to CF have been described in the medical literature. Prior formulations of pancrelipase have also demonstrated clinical efficacy in those patients through years of clinical experience. PERTs work in patients with EPI by delivering pancreatic enzymes to the small intestine to help break down fats, proteins and carbohydrates in food, thereby acting as a replacement for digestive enzymes physiologically secreted by the pancreas. EPI can occur as a complication of a variety of diseases or conditions, including CF, pancreatic cancer, gastrointestinal surgery and chronic pancreatitis. Statistics show that more than 80% of CF patients have EPI, which usually develops during the first year of life.

The original products in the pancreatic enzyme drug class pre-date modern FDA regulatory requirements. Over the past two decades, products in this class have been allowed to be marketed as prescription drugs without formal NDA approval. In 2004, the FDA required manufacturers to submit New Drug Applications (NDAs) for all panc
'/>"/>

SOURCE Solvay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Results Published In Journal of Cystic Fibrosis Confirm CREON(R) (pancrelipase) Delayed-Release Capsules Improves Fat Absorption in Patients With Cystic Fibrosis
2. Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets
3. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
4. GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer
5. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
6. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
7. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
8. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
9. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
10. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
11. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...   Health 2.0 announces Bernard Tyson , ... Eric Topol , Patrick Soon-Shiong , and Samsung,s ... 8th Annual Fall Conference this coming Sept. 21-24 in ... 2.0 is set to host the very first Wearable Tech ... Consumer Tech & Wearables: Powering Healthy Lifestyles. The ...
(Date:7/28/2014)... July 28, 2014 Anthera Pharmaceuticals, Inc. (NASDAQ: ... for the second quarter ended June 30, 2014. ... 2014 was $7.3 million, compared to $8.3 million for the ... a direct result of a decrease in interest expense in ... six months ended June 30, 2014 was $15.2 million, compared ...
(Date:7/28/2014)... SHORT HILLS, N.J. , July 28, 2014 ... announced a $520,000 settlement of off-label marketing and ... Justice ("DOJ") and Vascular Solutions, Inc. ("VSI").  The ... of various medical devices for endovenous laser ablation ... Stone & Magnanini, a firm with a history ...
Breaking Medicine Technology:Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 2Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 4Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 5Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 6Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 7Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 2Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 3
... initiate Phase 1 trial of AKIi-5 as the first ... ... Aug. 2 Quark Pharmaceuticals, Inc., a,clinical-stage biopharmaceutical company ... today the,presentation of positive results from preclinical efficacy studies ...
... PHILADELPHIA, Aug. 3 GlaxoSmithKline (NYSE:,GSK), one of ... has placed another order to purchase bulk H5N1 ... The company also announced the,start of the first ... pre-pandemic influenza program. HHS Order The ...
Cached Medicine Technology:Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 2Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 3Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 4GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 2GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 3GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 4
(Date:7/29/2014)... 29, 2014 PeopleKeys today announced that ... teach students how to train and certify others in ... Behavioral Consultant Trainer , will be taught by PeopleKeys ... Training John Schindell as a live Tele-course over the ... The Certified Behavioral Consultant Trainer course will use a ...
(Date:7/29/2014)... In today’s world, a good night’s sleep has ... sleep apnea (a medical problem where the airway collapses during ... of the rest they need to face their daily challenges. ... 20 million people in the United States alone have sleep ... and of those treated, many cannot tolerate their prescribed medical ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 In its ... offers treatment programs and believes that having family close ... big difference in whether or not the process is ... myths. , “It’s difficult to estimate just how damaging ... Rehabilitation’s CEO Per Wickstrom . “Not only do ...
(Date:7/29/2014)... 2014 Nuanced Media, a leading digital ... HIPAA (Health Insurance Portability and Accountability Act) certified firm. ... storage and transfer of Personal Health Information (PHI). ... Nuanced Media can effectively serve their medical industry clients. ... to offer medical industry specific products such as ...
(Date:7/29/2014)... brides want their bridal dresses and bridal parties to ... sure to provide designs of wedding gowns and bridesmaids ... has recently announced its new collection of gorgeous lace ... come with big savings, up to 61% off. , ... working in the garment industry for several years; they ...
Breaking Medicine News(10 mins):Health News:PeopleKeys Announces New Certified Behavioral Consultant Trainer Course 2Health News:PeopleKeys Announces New Certified Behavioral Consultant Trainer Course 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Latest Best Drug Rehabilitation Blog Post Busts 4 Big Addiction Myths 2Health News:Latest Best Drug Rehabilitation Blog Post Busts 4 Big Addiction Myths 3Health News:Nuanced Media Web Design Agency Now Hipaa Certified 2Health News:LunaDress’ Summer Sale Has Arrived: All Its Gorgeous Lace Wedding Dresses are Affordable Now 2
... Epidemiologists have long warned that, in addition to causing ... person at greater risk for colon cancer. Now, researchers ... explain why. The findings, "Epigenetic Differences in Normal ... Pathways," were published in the March issue of the ...
... HIV-positive patient, one of her first questions is whether he ... response is about dead relatives or friends. "We talk about ... experience will be very different," said the infectious-disease specialist at ... "Yes it,s the same virus and could have the same ...
... Researchers from Boston University School of Medicine (BUSM) and ... breast pain who receive imaging (mammograms, MRIs or ultrasounds) ... testing, but do not gain benefit from these additional ... of General Internal Medicine. Breast pain is ...
... -- Exposure to cocaine, tobacco or marijuana before birth ... tests, according to a new study. Prenatal alcohol ... fetal alcohol syndrome, was associated with lower scores at ... researchers found. The negative associations between intrauterine alcohol ...
... Reporter , TUESDAY, March 6 (HealthDay News) -- New research ... longevity in humans by showing that genetically modified mice live ... a few differences between mice and humans, especially in regard ... genetic tweak, so there,s no way to know if the ...
... -- When faced with stressful situations, older adults who sleep ... a new study finds. The marker, called interleukin-6 (IL-6), ... as cardiovascular disease, diabetes and psychiatric problems. "Our study ... sleep and what poor sleep may be doing to our ...
Cached Medicine News:Health News:Study shows how high-fat diets increase colon cancer risk 2Health News:Federal grant enables HIV testing, treatment in the Augusta area 2Health News:Federal grant enables HIV testing, treatment in the Augusta area 3Health News:Research finds little benefit of breast imaging tests for women with breast pain 2Health News:Fetal Cocaine Exposure May Not Affect Kids' Academics: Study 2Health News:Genetic Tweak Helps Mice Avoid Cancer, Obesity: Study 2Health News:Poor Sleep May Impact Stress Response in Older Adults 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: